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Microbiota-Gut-Brain Axis: Is Gut Microbiota Correlated with Major 
Depressive Disorder (MDD)?
INTRODUCTION
The gut microbiota is crucial during the development of the nervous system and has influence, through the microbiota-gut-brain axis, on several psychological disorders such as anxiety, major depressive
disorder (MDD), schizophrenia and autism spectrum disorder (ASD). MDD is a debilitating disease that is characterized by one or more discrete depressive episodes of at least two weeks’ duration involving
clear-cut changes in affect, cognition, and vegetative symptoms. Some of the biological dysregulations associated to depression affect the inflammatory and oxidative stress, metabolism, Hypothalamic-Pituitary-
Adrenal (HPA) axis, and neurotransmitter and neuropeptide production; which are all processes modified by the gut microbiota. In addition to that, psychobiotics are probiotics that confer a health benefit on
patients with psychiatric problems when administered in adequate doses. Psychobiotics are being studied as a potential alternative for treatments that present adverse symptoms such as tryptophan
supplementation, or as supplements for treatments with tricyclic antidepressants and monoamine oxidase inhibitors.
Methodology: For the realization of the present review, a systematic data research was carried out mainly in Pubmed database provided by the National Center for Biotechnology Information, ScienceDirect and GoogleScholar.
Objectives: 1) The main objective is to answer the question: Is gut microbiota correlated with Major Depressive Disorder (MDD)?; 2) Gather information from trustworthy sources in order to write up a complete report about the crosstalk
between the gut and the brain through the Microbiota-Gut-Brain; 3)Gain knowledge about the effect that gut microbiota upon Major Depression Disorder, as well as its mechanisms of action; 4) Review which probiotics can be used to
ameliorate depressive-like behaviors and its future clinical perspectives.
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➢ Depression is a multifactorial disorder that has several possible causes, which are related and influenced by each other.
➢ Studies on the crosstalk between gut microbiota and CNS focusing on depression, bring up interesting results and promising
research lines that might help us to elucidate which are the causes, mechanisms and consequences of depression.
➢ Depression can potentially be caused by a dysregulation in the tryptophan metabolization as a consequence of a gut
microbiota dysbiosis, which ultimately causes a decrease in serotonin production. Therefore, there is a correlation between
gut microbiota and MDD.
➢ Psychobiotics can be used as a treatment or treatment supplementation in order to ameliorate depressive-like symptoms and
promote serotonin production.
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Tryptophan is an essential amino acid that must be
supplied in the diet, since eukaryotes do not generate
the enzyme needed for its synthesis. Then it can be
accumulated and used in two different body regions:
1) It can be absorbed in the gut, put into circulation
and cross the blood brain barrier and participates
in serotonin synthesis in the CNS.
2) It is used to produce serotonin in the
enterochromaffin cells of the gastrointestinal tract.
However, tryptophan metabolism is separated into
two pathways: the kynurenine and serotonin pathways
(KYN and 5-HT respectively).
Kelly et al, carried out a study in which patients
suffering from depression showed increased plasma
levels of IL-1, IL-6 and TNFα, as well as a higher
KYN/TRP ratio compared to control individuals. Hence,
a correlation can be established between the
increased level of these cytokines and the induction of
the enzyme indoleamine-2,3-dioxygenase (IDO), which
consequently has an impact in the KYN/TRP ratio, and
ultimately, in serotonin production.
Data from animal studies provides evidences that gut
microbiota may impact the neurobiological features of
depression, such as: low-grade immune activation, HPA
axis activity, altered tryptophan metabolism, amongst
others. Experimental data suggests a complex
bidirectional interaction between the gastrointestinal
tract and the central nervous system (CNS), commonly
named “Gut-Brain axis”. Given that it has also been seen
a role of the gut microbiota in this interaction, the term
MGB axis was coined.
Within the world of probiotics there is a subgroup denoted as
psychobiotics, which confer a health benefit to patients with
psychiatric problems when administered in adequate doses.
Desbonnet et al., 2008 assessed the potential antidepressant
properties of Bifidobacterium infantis 35624 in rats, and the
overall results of the study are the following:
1) B. infantis administration caused an IFN-γ production
suppression, which was accompanied by an increase in
plasma tryptophan.
2) A decrease in the kynurenine:tryptophan ratio suggests a
reduced activity of IDO, which is likely to be due to the
reduced levels of pro-inflammatory cytokines.
3) Increase in the kynurenic acid:kynurenine ratio, which is
known as the neuroprotective ratio, due to an up-regulation
of kynurenic acid production upon probiotic treatment
Figure 4. Tryptophan metabolization pathways. indoleamine-2,3-dioxygenase (IDO), tryptophan-2,3-dioxygenase
(TDO), tryptophan hydroxylase (TPH), aromatic amino acid decarboxylase (AAAD)
Figure 1. DSM-5 book cover
Figure 3. Microbiota-Gut-Brain axis and its brain to gut (blue arrows) and gut
to brain (green arrows) communication pathways. Adapted from Winter et
al., 2018.
Figure 5. Graph a) shows tryptophan, L-kynurenine and kynurenic acid levels in plasma (ng/ml). Graph
b) shows L-kynurenine/tryptophan and kynurenic acid/kynurenine rations. Grey bars refer to rats
supplemented with Bifidobacterium infantis. Extracted from Desbonnet et al., 2008
Figure 2. Most abundant bacterial phyla present in human gut
and its alterations in depression
HOW IS MDD DIAGNOSED?
Presence of 2 or more symptoms during 2 weeks
Symptoms cause distress and impairment
Episode is not caused by drugs or medical condition
Episode is not explained by other mental disorders
Individual has never had a maniac episode
